A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND133688, NSC102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
Latest Information Update: 30 Dec 2024
Price :
$35 *
At a glance
- Drugs Azacitidine (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Cytarabine; Daunorubicin; Dexamethasone; Dexamethasone; Dexamethasone; Folinic acid; Folinic acid; Hydrocortisone sodium succinate; Mercaptopurine; Mercaptopurine; Methotrexate; Methotrexate; Methotrexate; Pegaspargase; Pegaspargase; Prednisolone; Prednisolone; Tioguanine; Tioguanine; Vincristine
- Indications Acute biphenotypic leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 27 Dec 2024 Planned End Date changed from 22 Sep 2024 to 25 Nov 2025.
- 26 Sep 2023 Planned End Date changed from 9 Jun 2024 to 22 Sep 2024.
- 23 Jun 2023 Planned End Date changed from 9 Jun 2023 to 9 Jun 2024.